A Wyoming overview of physician-supervised GLP-1 treatment through Astra, including local access context and the cities we cover. Every statistic on this page links to its source.
Nearly one in three adults in Wyoming — 32.5%, per the 2024 CDC BRFSS release 5 — live with obesity. That's down slightly from a peak of 34.3% in 2022 and 33.3% in 2023, but it's well above the 27.7% Wyoming reported in 2016 56. Across eight years of state surveillance, the trend has one direction: up.
For most Wyoming adults, that rising prevalence doesn't translate into Medicaid-covered treatment. Wyoming Medicaid's Preferred Drug List, effective January 1, 2026, files every GLP-1 — Rybelsus, Trulicity, and Victoza as preferred agents; Ozempic, Mounjaro, and Bydureon as non-preferred — under "Incretin Mimetics (GLP-1 Receptor Agonists)" in the Diabetes therapeutic class only 1. There is no obesity or weight-management indication anywhere in that section.
The state's Additional Therapeutic Classes with Clinical Criteria chart, last updated June 8, 2026, names the two GLP-1s Medicaid will pay for outside diabetes, and neither covers obesity as a stand-alone diagnosis. Wegovy requires a BMI of 27 or higher with established cardiovascular disease — a prior heart attack, stroke, or peripheral artery disease — reflecting the drug's CV-risk-reduction label, not its weight-loss one. Zepbound requires moderate-to-severe obstructive sleep apnea, confirmed by a sleep study showing an Apnea-Hypopnea Index above 15, with a second prior authorization at 6 months and a third sleep study at 12 months 2.
Wyoming's own Preferred Drug List separately footnotes Wegovy under a MASH — metabolic-associated steatohepatitis — indication elsewhere in the same document 1, which isn't fully reconciled with the newer chart's cardiovascular-only standard 2. Two current state documents, two different stories on the same drug; we report the more recent, more specific one and flag the footnote rather than hiding it.
Layered on top: Wyoming has not adopted the ACA's Medicaid expansion. State eligibility rules limit working-age adult Medicaid to parents and caretaker relatives who meet income tests, people with qualifying disabilities, or those in the WHIPP program, which itself requires you already have employer coverage 3. There's no general low-income adult category. So for childless, non-disabled Wyoming adults between jobs or between insurance, Medicaid isn't a path to GLP-1 coverage regardless of the drug list — they're not Medicaid-eligible at all 34.
Astra's pricing doesn't change based on where you live. Semaglutide is $68 a month and tirzepatide is $118 a month, both on 12-month plans billed annually at $816 and $1,416. That's the same price in Cheyenne, Casper, Jackson, or anywhere else in the state — Astra is licensed to treat patients in all 50 states, so Wyoming residents have the same access as residents of any other state, with no need to find a local prescriber first.
Wyoming-specific telehealth prescribing and informed-consent requirements for GLP-1 care haven't been independently verified for this page. TODO before publish: confirm current rules with the Wyoming Board of Medicine and replace this note with the verified specifics and citation.
Astra is licensed in all 50 states, Wyoming included. Intake, prescribing, and delivery happen without an in-person visit, which matters more in a state where the nearest prescriber can be a long drive away.
Astra treats patients in Wyoming through state-licensed physicians.
Wyoming is the least populous state in the country — 587,618 residents in the Census Bureau's Vintage 2024 estimate [7], fewer than Vermont, Alaska, North Dakota, or D.C. Its largest city and capital, Cheyenne (population 65,704) [8], is the only Wyoming city with its own dedicated GLP-1 page so far.
Not for weight loss alone. Wyoming Medicaid's Preferred Drug List (effective Jan. 1, 2026) places every GLP-1 — Rybelsus, Trulicity, and Victoza as preferred; Ozempic, Mounjaro, and Bydureon as non-preferred — strictly in the diabetes drug class, with no obesity indication anywhere in that section. Under the state's Additional Therapeutic Classes chart (updated June 8, 2026), Wegovy is approved only for a BMI of 27+ with documented cardiovascular disease, and Zepbound only for moderate-to-severe obstructive sleep apnea confirmed by a sleep study. On top of that, Wyoming never adopted the ACA's Medicaid expansion, so most childless, non-disabled working-age adults aren't Medicaid-eligible in the first place, regardless of what the drug list allows.
No — Astra's pricing is national and does not change by state or city. Semaglutide is $68/month and tirzepatide is $118/month, both billed as 12-month plans ($816 and $1,416 paid annually). A patient in Cheyenne, Casper, or Gillette pays exactly the same rate as a patient in any other state.
CDC BRFSS state estimates can shift a few points year to year due to normal survey variation, so it's worth looking at the trend rather than one reading: Wyoming adult obesity rose from 27.7% in 2016 to a peak of 34.3% in 2022, eased to 33.3% in 2023, and sits at 32.5% in the latest 2024 release — a clear multi-year rise even accounting for year-to-year noise.
Yes. Astra is licensed to treat patients in all 50 states, including every part of Wyoming — the least populous state in the country at 587,618 residents. You don't need to live near Cheyenne or travel to a specialist; consults, prescribing, and follow-up all happen online.
Check the Cheyenne page for the closest thing to a local market snapshot in Wyoming today, including Laramie County obesity data and any GLP-1 pricing clinics there publish on their own sites, with sources and the date each was checked.
Last reviewed:
Educational information, not medical advice. Treatment requires evaluation by a licensed physician.